5 Common Mistakes in MFDS Class II Submissions for Foreign Manufacturers

Why Class II Submissions Stall

MFDS Class II (제2등급 의료기기) requires product registration (허가) through a Korea License Holder (KLH). The review queue at MFDS averages 60–90 days for clean dossiers, but every deficiency notice (보완요구) resets the clock by 30–60 days.

In 12 foreign manufacturer submissions we observed in 2024–2025, the same five gaps appeared in 8 of the 12 deficiency letters issued.

The 5 Mistakes

1. Submitting CE/FDA Technical Files Without MFDS Reformatting

The mistake: Submitting CE Annex II files or FDA 510(k) sections in their original format with cover translation.

Why MFDS rejects: Korean STED requires (a) a Korea-specific risk management summary referencing ISO 14971:2019 mapped to Korean Medical Device Law Article 12, (b) explicit declarations of compliance with KMD safety and performance standards, and (c) Korean-language device descriptions in MFDS-approved terminology.

The fix: Use existing CE/FDA files as source material, not as the submission itself. Restructure into the 8-section MFDS STED format.

2. Missing or Inadequate Korean Clinical Evaluation

The mistake: Submitting EU MDR Clinical Evaluation Reports (CER) translated word-for-word.

Why MFDS rejects: MFDS requires the clinical evaluation to address (a) Korean patient population relevance, (b) clinical performance comparisons with devices already approved in Korea, and (c) Korean-specific clinical literature when available.

The fix: Adapt CER content to Korean clinical context. Add a 2–3 page section on Korea-specific equivalence to existing MFDS-approved devices.

3. Labeling and IFU Not Compliant with MFDS Format

The mistake: Direct translation of CE-marked IFU with the CE mark removed.

Why MFDS rejects: Korean labeling must include MFDS product license number (issued upon approval, so use placeholder during submission), KLH name and address (in Korean), Korean-language warnings using MFDS-mandated phrasing, and storage conditions in Celsius with Korean units.

The fix: Build IFU from MFDS Notice 2022-110 (의료기기 표시·기재 가이드라인) requirements rather than translating CE IFU.

4. Underestimating KGMP Inspection Coordination

The mistake: Submitting product registration without scheduling KGMP foreign site inspection in parallel.

Why submissions stall: Class II Korean registration requires a valid KGMP certificate for the manufacturing site. Without KGMP, MFDS will issue conditional approval pending inspection — which can delay market entry by 4–6 months.

The fix: Initiate KGMP application simultaneously with product registration. Coordinate KGMP and product registration timelines.

5. Korea License Holder (KLH) Documentation Gaps

The mistake: Distributor named as KLH without formal KLH agreement or with incomplete authorization documentation.

Why MFDS rejects: MFDS verifies that the KLH has a legally executed agreement granting full license-holder authority, a Korean business registration (사업자등록), and post-market obligations capacity (vigilance, change notifications, recalls).

The fix: Use either a distributor with verified KLH capacity OR an independent KLH service that decouples regulatory standing from commercial relationships.

Comparison: Common Mistakes by Frequency

Mistake	Frequency in 12 Reviews	Avg. Delay Added
1. CE/FDA file format not reformatted	10/12	60 days
2. Clinical evaluation Korea-context missing	8/12	45 days
3. Labeling/IFU non-compliant	7/12	30 days
4. KGMP not scheduled in parallel	6/12	120 days
5. KLH documentation incomplete	5/12	45 days

Pre-Submission Checklist

Before filing MFDS Class II registration:

1. ✅ STED reformatted to MFDS 8-section structure
2. ✅ Risk Management File references ISO 14971:2019 + Korean Medical Device Law
3. ✅ Clinical Evaluation Report adapted for Korean clinical context
4. ✅ Korean IFU built from MFDS Notice 2022-110 requirements
5. ✅ KGMP application initiated for manufacturing site
6. ✅ KLH agreement signed and KLH business registration verified
7. ✅ Korean labels include MFDS-mandated warnings in approved phrasing
8. ✅ Korean medical device terminology consistent with MFDS dictionary

Frequently Asked Questions

Q: How long does an MFDS Class II review take if everything is correct?

A: 60–90 calendar days from submission acceptance. The clock pauses during deficiency notice rounds, which typically add 30–60 days per round.

Q: Can we use the same Clinical Evaluation Report we submitted to EU MDR?

A: Not directly. EU MDR CER provides the core clinical evidence, but MFDS requires an adapted version addressing Korean patient population relevance and comparisons with devices already approved in Korea. Expect 2–3 additional pages of Korea-specific content.

Q: Is KGMP required for all Class II devices?

A: Yes. All Class II, III, and IV devices require KGMP certification for the manufacturing site. Class I devices are exempt under the notification (신고) pathway.

Q: How much does MFDS Class II registration cost?

A: MFDS official fees range from ₩4M–₩8M ($3,000–$6,000) depending on technical review complexity. Total program cost (including consulting, documentation prep, KGMP, and KLH services) typically runs $30,000–$80,000 for foreign manufacturers.

Q: Can Leanabl review my draft submission before we file?

A: Yes. Leanabl's Technical Documentation & Registration service includes pre-submission review against the 5 mistakes above plus 40+ additional MFDS-specific criteria.

How Leanabl Helps

For companies preparing MFDS Class II submissions:

• Korea Medical Device Registration — end-to-end MFDS registration including STED preparation
• KGMP Certification — foreign manufacturing site certification
• KLH Service — independent Korea License Holder decoupled from distributors
• Technical Documentation & Registration — STED authoring and submission management

Contact Leanabl for a pre-submission readiness review.

---

Last updated: 2026-05-15.